Dane Leone
Stock Analyst at Raymond James
(1.28)
# 3,457
Out of 4,876 analysts
82
Total ratings
38.1%
Success rate
-5.88%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.68 | +492.33% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.39 | +436.35% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $128.11 | -21.94% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $36.91 | -18.72% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $521.00 | +82.34% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.66 | +683.13% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $44.86 | +2.54% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $28.01 | +146.34% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.30 | +778.79% | 2 | Apr 19, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $2.56 | +212.50% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $9.22 | +51.84% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $8.14 | +612.53% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $16.86 | +315.18% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.18 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $33.16 | +89.99% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.35 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.17 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $40.35 | +61.09% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.15 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $277.13 | -7.99% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $2.96 | +981.08% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $152.41 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.68
Upside: +492.33%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.39
Upside: +436.35%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $128.11
Upside: -21.94%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $36.91
Upside: -18.72%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $521.00
Upside: +82.34%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.66
Upside: +683.13%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $44.86
Upside: +2.54%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $28.01
Upside: +146.34%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.30
Upside: +778.79%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $2.56
Upside: +212.50%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $9.22
Upside: +51.84%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $8.14
Upside: +612.53%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $16.86
Upside: +315.18%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.18
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $33.16
Upside: +89.99%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $46.35
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.17
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $40.35
Upside: +61.09%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $9.15
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $277.13
Upside: -7.99%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $2.96
Upside: +981.08%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $152.41
Upside: -